Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TSHA
STRONG SELLTaysha Gene Therapies, Inc. · Healthcare · United States · $1.6B · Avg Vol: $21M/d
COMPANY DESCRIPTION
Taysha Gene Therapies, Inc. is a clinical-stage gene therapy company focused on developing therapies for monogenic central nervous system (CNS) diseases. The company utilizes a robust adeno-associated virus (AAV) gene therapy platform to address a range of neurological disorders with high unmet medical needs. Taysha operates as a specialized player in the burgeoning gene therapy sector, aiming to deliver potentially curative treatments for severe inherited brain disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.5M | 15.5M | 8.3M | 9.8M | 57.5% | 7.5M | 1.8M | 29.7M | 74.4% |
| EPS | -0.83 | -0.96 | -0.36 | -0.34 | — | -0.36 | -0.44 | -0.43 | — |
| Shares | 287.4M | 187.0M | 204.9M | 285.1M | -0.8% | 287.4M | — | — | — |
| Debt | 59.9M | 61.1M | 63.2M | 70.1M | 5.4% | 68.6M | — | — | — |
| Equity | 0.9M | 74.9M | 71.5M | 246.9M | 538.4% | — | — | — | — |
| Op CF | -88.4M | -73.0M | -81.2M | -93.1M | — | -111.9M | — | — | — |
| Inv CF | -24.9M | -7.4M | -0.4M | -0.6M | — | — | — | — | — |
| Fin CF | 52.1M | 136.4M | 76.7M | 274.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TSHA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc.(you) | $1.6B | 18 | STRONG SELL |
| ZYME | Zymeworks Inc. | $1.7B | 19 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 17 | STRONG SELL |
| NTLA | Intellia Therapeutics, Inc. | $1.5B | 15 | STRONG SELL |
| TYRA | Tyra Biosciences, Inc. | $1.8B | 20 | SELL |
| PGEN | Precigen, Inc. | $1.9B | 17 | STRONG SELL |
| ZBIO | Zenas BioPharma, Inc. | $1.9B | 16 | STRONG SELL |
| BHVN | Biohaven Ltd. | $2.2B | 19 | STRONG SELL |
| CAPR | Capricor Therapeutics, Inc. | $1.1B | 18 | STRONG SELL |
| MPLT | MapLight Therapeutics, Inc. | $1.7B | 25 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%